Weight Management
Tirzepatide
Physician-supervised compounded dual GIP/GLP-1 therapy for weight management.
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for weight management and blood-sugar control. The Pep Club dispenses a compounded preparation of the active ingredient under U.S.-licensed physician supervision.
About this medication
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The active pharmaceutical ingredient is the same molecule that appears in brand-name medications such as Mounjaro and Zepbound. The Pep Club dispenses a compounded preparation of this ingredient through a licensed compounding pharmacy under U.S.-licensed physician supervision. The dual mechanism engages two complementary incretin pathways. The brand-name products have been studied in the SURMOUNT clinical trial program for weight management and in the SURPASS trial program for type 2 diabetes. The compounded preparation has not undergone equivalent finished-product efficacy testing; outcomes from those trials should not be assumed to transfer one-for-one to a compounded preparation. The Pep Club dispenses compounded tirzepatide through a licensed pharmacy partner with physician-supervised dose titration and regular telehealth monitoring. Our approach emphasizes gradual dose escalation to maximize tolerability. Each patient receives a treatment protocol based on their medical history, current medications, and weight-management goals.
How it works
Tirzepatide is a 39-amino acid linear peptide that acts as a dual agonist at both GIP and GLP-1 receptors. Its GIP receptor activity (approximately 5x native GIP potency) enhances fat metabolism in adipose tissue, improves insulin sensitivity in peripheral tissues, and may have direct effects on central appetite regulation through hypothalamic GIP receptors. Its GLP-1 receptor activity (comparable to native GLP-1) slows gastric emptying, promotes satiety through hypothalamic POMC neuron activation, and enhances glucose-dependent insulin secretion. The C20 fatty diacid moiety enables albumin binding, extending the half-life to approximately 5 days for once-weekly dosing. The dual mechanism produces additive effects on weight loss and glycemic control that exceed either pathway alone.
Clinical research context
The clinical-trial evidence for tirzepatide weight management was developed for the brand-name finished product, not for any compounded preparation. The SURMOUNT trial program evaluated brand-name tirzepatide for weight management across adults with and without type 2 diabetes, including comparisons with and without intensive behavioral therapy. The SURPASS trial program studied brand-name tirzepatide in type 2 diabetes alongside multiple active comparators. The compounded preparation dispensed by The Pep Club has not undergone equivalent finished-product efficacy or safety testing; brand-name trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from the compounded preparation. Your physician will discuss realistic expectations at consultation.
What patients describe
- Dual GIP/GLP-1 mechanism engages two complementary incretin pathways
- Studied for weight management in brand-name clinical trials
- Reduction in waist circumference and visceral adiposity reported in brand-name studies
- Improved insulin sensitivity and glycemic control studied in brand-name diabetes trials
- Cardiovascular risk-factor improvements (blood pressure, lipids) reported in brand-name data
- Designed for adherence with a consistent weekly schedule set by your physician
- Improvements in non-alcoholic steatohepatitis (NASH) biomarkers reported in brand-name studies
- Potential reduction in obstructive sleep apnea severity reported in brand-name studies
Side effects
- Nausea (most common, usually diminishes over 4-8 weeks)
- Diarrhea
- Decreased appetite (therapeutic but can be pronounced at higher doses)
- Vomiting, especially during dose escalation periods
- Constipation
- Abdominal pain or dyspepsia
- Injection site reactions
- Hair thinning (reported in some patients during rapid weight loss)
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to tirzepatide or its excipients
- History of pancreatitis or active gallbladder disease
- Pregnancy or planning to become pregnant (discontinue at least 2 months before)
- Breastfeeding
- Severe gastrointestinal disease or gastroparesis
- Diabetic retinopathy requiring active treatment (may worsen transiently)
Drug interactions
- Insulin and sulfonylureas - significant hypoglycemia risk; dose adjustment typically required
- Oral contraceptives - delayed gastric emptying may reduce bioavailability; use non-oral contraception
- Warfarin and other anticoagulants - monitor INR closely during initiation
- Oral medications with narrow therapeutic index - timing of absorption may be altered
- Acetaminophen - peak absorption delayed; clinical significance is minimal
Storage
Follow the storage instructions provided by your pharmacy and on the medication label. Do not use if the solution is cloudy, discolored, or contains visible particles.
Frequently asked
How does tirzepatide compare to semaglutide for weight management?
Cross-trial analysis of the brand-name products suggests tirzepatide at higher doses may produce greater weight reduction than semaglutide, attributed to its dual GIP/GLP-1 mechanism. Both molecules have substantial brand-name trial evidence. The choice between the two compounded preparations depends on individual response, tolerability, medical history, and physician judgment; outcomes from a compounded preparation are not guaranteed to match brand-name trial results.
Why is tirzepatide more expensive than semaglutide?
Tirzepatide is a newer, more complex 39-amino-acid molecule with dual receptor activity. The compounding process requires precise formulation. The Pep Club pricing reflects the pharmacy partner cost. Physician consultations are billed separately or included with a PepWell+ membership.
Can I switch from semaglutide to tirzepatide?
Switching is possible and is sometimes considered for patients who have plateaued on semaglutide. Your physician will create a transition plan tailored to your situation, including any washout period and the appropriate starting point for tirzepatide.
Does tirzepatide help with type 2 diabetes?
The brand-name product Mounjaro is marketed for type 2 diabetes; the brand-name product Zepbound is marketed for chronic weight management. The SURPASS brand-name trials reported HbA1c reductions in type 2 diabetes. The compounded preparation has not undergone equivalent finished-product testing. If you have both obesity and type 2 diabetes, discuss your full medical history with your Pep Club physician.
What weight changes can I expect?
Brand-name trial data reported a range of weight changes depending on dose and population. Outcomes from a compounded preparation cannot be guaranteed to match those trial results. Individual results vary significantly based on genetics, starting weight, adherence, diet, physical activity, and sleep quality. Your Pep Club physician will set realistic expectations at consultation.
Where we can ship
Available in every state where The Pep Club has a licensed physician and a licensed pharmacy partner. Check the state availability page for the current list.
Ready to talk to a physician?
Start with our short eligibility intake. If you qualify, a licensed physician reviews your history before any prescription is issued.